WuXi Biologics partners with AstraZeneca on Evusheld in China

5 August 2022

Shares of Chinese contract research, development and manufacturing organization (CRDMO) WuXi Biologics (HK: 2269) rose more than 5% yesterday, after the Chinese vaccine maker said it is partnering with AstraZeneca (LSE: AZN) to produce the UK pharma major’s COVID-19 preventive drug, that was approved by Chinese regulatory authorities last month, according to a report by Yicai Global.

Wuxi Biologics, which boasts world-class biological agent production services, will ensure future supplies of Evusheld (tixagevimab/cilgavimab) in China to benefit more people who have low immunity and are not suitable for vaccination, said Wang Lei, global executive vice-president and China president of AstraZeneca.

China authorized the use of Evusheld, a neutralizing antibody cocktail that is effective for six months, by two hospitals in a medical tourism zone in the getaway island province of Hainan in early July. It is the first such antibody treatment to be imported into the country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK